1. Home
  2. NUVL vs AMG Comparison

NUVL vs AMG Comparison

Compare NUVL & AMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NUVL
  • AMG
  • Stock Information
  • Founded
  • NUVL 2017
  • AMG 1993
  • Country
  • NUVL United States
  • AMG United States
  • Employees
  • NUVL N/A
  • AMG N/A
  • Industry
  • NUVL Biotechnology: Pharmaceutical Preparations
  • AMG Investment Managers
  • Sector
  • NUVL Health Care
  • AMG Finance
  • Exchange
  • NUVL Nasdaq
  • AMG Nasdaq
  • Market Cap
  • NUVL 6.5B
  • AMG 6.8B
  • IPO Year
  • NUVL 2021
  • AMG 1997
  • Fundamental
  • Price
  • NUVL $98.17
  • AMG $236.68
  • Analyst Decision
  • NUVL Strong Buy
  • AMG Strong Buy
  • Analyst Count
  • NUVL 11
  • AMG 5
  • Target Price
  • NUVL $121.45
  • AMG $273.00
  • AVG Volume (30 Days)
  • NUVL 527.5K
  • AMG 205.4K
  • Earning Date
  • NUVL 10-30-2025
  • AMG 11-03-2025
  • Dividend Yield
  • NUVL N/A
  • AMG 0.02%
  • EPS Growth
  • NUVL N/A
  • AMG N/A
  • EPS
  • NUVL N/A
  • AMG 13.84
  • Revenue
  • NUVL N/A
  • AMG $2,030,400,000.00
  • Revenue This Year
  • NUVL N/A
  • AMG $3.34
  • Revenue Next Year
  • NUVL N/A
  • AMG $9.48
  • P/E Ratio
  • NUVL N/A
  • AMG $17.10
  • Revenue Growth
  • NUVL N/A
  • AMG 0.11
  • 52 Week Low
  • NUVL $55.54
  • AMG $139.22
  • 52 Week High
  • NUVL $104.90
  • AMG $250.15
  • Technical
  • Relative Strength Index (RSI)
  • NUVL 60.96
  • AMG 48.47
  • Support Level
  • NUVL $90.00
  • AMG $235.04
  • Resistance Level
  • NUVL $99.94
  • AMG $247.66
  • Average True Range (ATR)
  • NUVL 5.06
  • AMG 6.38
  • MACD
  • NUVL 0.69
  • AMG -0.49
  • Stochastic Oscillator
  • NUVL 66.81
  • AMG 34.95

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About AMG Affiliated Managers Group Inc.

Affiliated Managers Group offers investment strategies to investors through its network of affiliates. The firm typically buys a majority interest in small to mid-size boutique asset managers, receiving a fixed percentage of revenue from these firms in return. Affiliates operate independently, with AMG providing strategic, operational, and technology support, as well as global distribution. At the end of June 2025, AMG's affiliate network—which includes firms like Abacus Capital and Pantheon dedicated to private markets (which accounted for 19% of AUM), AQR Capital and Capula Investment Management in liquid alternatives (24%), and Harding Loevner, Tweedy Browne, Parnassus, and Yacktman in equities, multi-asset, and bond strategies (57%)—had $771 billion in managed assets.

Share on Social Networks: